NO20060915L - Stabile modifikasjoner av tegaserodhydrogenmaleat - Google Patents

Stabile modifikasjoner av tegaserodhydrogenmaleat

Info

Publication number
NO20060915L
NO20060915L NO20060915A NO20060915A NO20060915L NO 20060915 L NO20060915 L NO 20060915L NO 20060915 A NO20060915 A NO 20060915A NO 20060915 A NO20060915 A NO 20060915A NO 20060915 L NO20060915 L NO 20060915L
Authority
NO
Norway
Prior art keywords
tegaserodhydrogen
maleate
stable modifications
crystalline forms
stable
Prior art date
Application number
NO20060915A
Other languages
English (en)
Norwegian (no)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060915(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20060915L publication Critical patent/NO20060915L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
NO20060915A 2003-07-24 2006-02-24 Stabile modifikasjoner av tegaserodhydrogenmaleat NO20060915L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24
PCT/EP2004/008281 WO2005014544A1 (fr) 2003-07-24 2004-07-23 Modifications stables du maleate d'hydrogene tegaserod

Publications (1)

Publication Number Publication Date
NO20060915L true NO20060915L (no) 2006-04-24

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060915A NO20060915L (no) 2003-07-24 2006-02-24 Stabile modifikasjoner av tegaserodhydrogenmaleat

Country Status (24)

Country Link
US (1) US20070112056A1 (fr)
EP (2) EP1880992A1 (fr)
JP (1) JP2006528609A (fr)
KR (1) KR20060040710A (fr)
CN (1) CN1826318A (fr)
AR (1) AR045081A1 (fr)
AU (1) AU2004263285A1 (fr)
BR (1) BRPI0412830A (fr)
CA (1) CA2532351A1 (fr)
CO (1) CO5680418A2 (fr)
EC (1) ECSP066306A (fr)
IL (1) IL172914A0 (fr)
IS (1) IS8321A (fr)
MA (1) MA27935A1 (fr)
MX (1) MXPA06000917A (fr)
MY (1) MY137386A (fr)
NO (1) NO20060915L (fr)
NZ (1) NZ544596A (fr)
PE (1) PE20050253A1 (fr)
RU (1) RU2349585C2 (fr)
SG (1) SG144944A1 (fr)
TN (1) TNSN06024A1 (fr)
TW (1) TW200510302A (fr)
WO (1) WO2005014544A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
WO2006083710A2 (fr) * 2005-01-31 2006-08-10 Novartis Ag Composes organiques
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
JP2008514734A (ja) * 2005-06-22 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド マレイン酸テガセロドの多型体
AR058078A1 (es) * 2005-10-06 2008-01-23 Medichem Sa Maleato de tegaserod y procesos de obtencion
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (fr) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Préparation de maléate de tegaserod exempt de iodure
EP1956002A1 (fr) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. Nouveaux polymorphes de maléate de tégasérod et leur procédé de préparation
CA2687209A1 (fr) * 2007-05-17 2008-11-27 Generics (Uk) Limited Procede de preparation de la forme a du tegaserode

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
WO2004085393A1 (fr) * 2003-03-25 2004-10-07 Hetero Drugs Limited Nouvelles formes cristallines de maleate de tegaserod
KR20060111675A (ko) * 2003-12-16 2006-10-27 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 염기 및 그것의 염의 다형태
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
JP2008514734A (ja) * 2005-06-22 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド マレイン酸テガセロドの多型体

Also Published As

Publication number Publication date
EP1651601A1 (fr) 2006-05-03
BRPI0412830A (pt) 2006-09-26
JP2006528609A (ja) 2006-12-21
SG144944A1 (en) 2008-08-28
TNSN06024A1 (en) 2007-10-03
CN1826318A (zh) 2006-08-30
CA2532351A1 (fr) 2005-02-17
AU2004263285A1 (en) 2005-02-17
RU2349585C2 (ru) 2009-03-20
MXPA06000917A (es) 2006-03-30
WO2005014544A1 (fr) 2005-02-17
EP1880992A1 (fr) 2008-01-23
CO5680418A2 (es) 2006-09-29
IL172914A0 (en) 2006-06-11
TW200510302A (en) 2005-03-16
ECSP066306A (es) 2006-07-28
US20070112056A1 (en) 2007-05-17
NZ544596A (en) 2009-01-31
MY137386A (en) 2009-01-30
PE20050253A1 (es) 2005-06-03
IS8321A (is) 2006-02-22
MA27935A1 (fr) 2006-06-01
AR045081A1 (es) 2005-10-12
RU2006105481A (ru) 2007-09-20
KR20060040710A (ko) 2006-05-10

Similar Documents

Publication Publication Date Title
NO20060915L (no) Stabile modifikasjoner av tegaserodhydrogenmaleat
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20080879L (no) HCV-NS3-proteaseinhibitorer
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20063928L (no) Substituerte kinolinforbindelser
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20024386L (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20083523L (no) Sammensetning for vaginal anvendelse
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20045042L (no) 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
EA200700673A1 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
NO20011254L (no) Kopolymerblandinger og deres anvendelse som additiv til forbedring av kaldflyteegenskapene til mellomdestillater
NO20080392L (no) Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1
WO2005000231A3 (fr) Antagonistes du recepteur il-8
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
WO2001072960A3 (fr) Recepteur d'antagonistes d'il-8
NO20011255L (no) Kopolymerblandinger og deres anvendelse som additiv til forbedring av kaldflyteegenskapene til mellomdestillater
WO2004039775A3 (fr) Antagonistes du recepteur il-8

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application